TOP STORIES
Citron remains the kingmaker – or, more accurately, the coup-maker – in the second half of 2015. Its tweet sent Mallinckrodt’s shares falling.
At these prices $MNK has signif more downside than $VRX— far worse offender of the reimb sys – more to follow. VRX can’t live in a vacuum
— Citron Research (@CitronResearch) November 9, 2015
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Does it prove there’s a bubble in the type of Valeant, Mallinckrodt-style business models and the backlash against high-price drugs is here to stay? Or does this prove public-markets investors are sheep? We’ll know more on Nov. 23, when earnings come out. – Financial Times, Bloomberg & MarketWatch
LIFE SCIENCES
AstraZeneca got good news on its would-be $1 billion lupus treatment anifrolumab. A mid-stage trial showed promise and AZ is moving on to a Phase III trial. – Reuters
Astellas Pharma will buy Ocata Therapeutics in an all-cash deal worth $379 million. – Xconomy
Vision Medicines has raised enough money for a first trial in its Stargardt disease treatment. – Xconomy
Aminex Therapeutics closed $4 million to advance its cancer immunotherapy treatment. – PR Newswire
ReliantHeart, which makes a left ventricular assist device, has raised on $2 million and could raise up to $14 million more. – Houston Business Journal
Eli Lilly’s diabetes treatment Jardiance helped type 2 diabetes patients cut the risk of heart-related death and other issues. – Reuters
PAYERS-PROVIDERS
Patients listen to advice based on their genetics – at least when it comes to heart disease. – Reuters
GE Healthcare has acquired The Camden Group. – Modern Healthcare
I like this article on patient simulators but it doesn’t have a single statistic or reference a single research study proving more realistic mannequins are cutting down on young doctors’ medical mistakes. Have you every seen one? – The New York Times
TECHNOLOGY
Two interesting insights on ResearchKit: the unique innovation of informed consent and its integration into apps for clinical research. – MobiHealthNews & Triangle Business Journal
Dorado Systems, which builds technology to connect the systems of payers and providers, has raised $8 million. – Philadelphia Business Journal
FitBit has a secondary offering that will largely help existing shareholders get liquid. – 247WallStreet
Patient-registration and management service Cureatr has expanded further in New York state. – Albany Business Review
Parenting app Baby Bundle raised nearly $2 million. – PE Hub
Dr. Peter Tippett, most recently the Verizon chief medical officer, has joined DataMotion’s board. – PR Newswire
A LITTLE BIT EXTRA
Trying to wrap your head around the state of race issues on college campus through the resignation of Missouri’s president? Oddly enough, a sports blog and The New York Times are delivering the most insight. – Deadspin & The New York Times
Photo: Flickr user James Barwell